Skip to content
MarketScale
‹ Back to IndustriesSciences

Why Microbes Can Be the Best Solution for Waterfloods, Saltwater Disposals and More

Bill Lantz worked for decades in the oil fields working with microbes. He saw just about every issue that can crop up, with companies often turning to chemicals to try and deal with waterflood, saltwater disposals, paraffin and more. Lantz founded JGL Solutions in 2006 after gaining experience utilizing a better solution – microbes….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · Bill Lantz PodcastMicrobesMicrobes in the OilfieldMicrobial Solutions
Share

Key takeaways

01

Bill Lantz worked for decades in the oil fields working with microbes.

02

He saw just about every issue that can crop up, with companies often turning to chemicals to try and deal with waterflood, saltwater disposals, paraffin and more.

03

Lantz founded JGL Solutions in 2006 after gaining experience utilizing a better solution – microbes….

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Bill Lantz worked for decades in the oil fields working with microbes.

He saw just about every issue that can crop up, with companies often turning to chemicals to try and deal with waterflood, saltwater disposals, paraffin and more. Lantz founded JGL Solutions in 2006 after gaining experience utilizing a better solution – microbes.

“They have a lot of (issues) that mostly they use chemicals to solve, and, once you know what these are and know there are microbes that actually do the same things chemicals do, only better, and do more than chemicals do, it’s really kind of amazing,” he said. “Being able to apply them at critical spots in a production spots and knowing what you’re doing … is a lot of it.”

The microbes provide not only a more effective solution but also one that is better for the environment, something many big energy companies love to hear as sustainability becomes more of a real focus and less of simply a buzzword.

“Now, you’re getting companies more worried about what they might actually be doing to the environment, so products like ours are perfect for that,” Lantz said. “What they’re finding out with our microbes is they’re more effective. Not only is it great for the environment, it’s much more effective than what they’re using, anyway.”

That makes looking into microbes as a solution for the issues that can occur in oil fields a smart play, and with Lantz and his team having decades of experience in the industry, JGL Solutions should be the first call.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech is investing $750 million in a new fill-finish plant in Hillsboro. The facility will focus on the production of prefilled syringes and autoinjectors. The site is expected to become operational in 2031.

  • 01Genentech is investing $750 million in a new Hillsboro facility.
  • 02The facility will produce prefilled syringes and autoinjectors.
  • 03Operations at the plant are expected to begin in 2031.

Aug 27, 2026

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio's cell-free hpDNA will be used by Genezen as starting material for viral vectors, potentially reducing the need for AAV input DNA by 30%. This innovation may lead to changes in the specification of plasmids and project timelines in gene therapy programs.

  • 01Genezen will utilize 4basebio’s cell-free hpDNA for viral vector production.
  • 02This approach could reduce AAV input DNA requirements by 30%.
  • 03The adoption of hpDNA could lead to changes in plasmid specification and project timelines.

Aug 27, 2026

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers has terminated its agreement with Cellares, which raises concerns about the standardized capacity for cell therapy production. This decision highlights the importance of aligning manufacturing processes with production capabilities, rather than merely focusing on the availability of factory slots.

  • 01Bristol Myers has terminated its agreement with Cellares, affecting cell therapy capacity.
  • 02Aligning process fit with production capabilities is crucial for cell therapy success.
  • 03Factory slots alone are not sufficient to ensure supply plans in cell therapy production.

Aug 26, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Daniel Litwin
Daniel Litwin

Editor, B2B Media

MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512